MedTrace Logo

TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension

NCT06646198 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-10-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) plus half-dose donafenib (a kind of anti-angiogenesis agents) in advanced hepatocellular carcinoma (BCLC-C Stage) accompanied by tumor thrombosis-associated portal hypertension.

Conditions

  • Hepatocellular Carcinoma with PVTT

Interventions

PROCEDURE

Transjugular intrahepatic portosystemic shunt (TIPS)

Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA

DRUG

Donafenib

Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.

Sponsors & Collaborators

  • Fei Gao

    lead OTHER

Principal Investigators

  • Fei Gao, M.D.，Ph.D. · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-08
Primary Completion
2026-05-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06646198 on ClinicalTrials.gov